Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05555121
Other study ID # IIS-1032
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date December 1, 2022
Est. completion date June 30, 2026

Study information

Verified date January 2024
Source Clinique Ovo
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Endometrin is a progesterone supplement prescribed during in vitro fertilization (IVF) for preparation for embryo transfer. The usual dose of Endometrin is 100 mg two to three times per day in the form of an effervescent tablet to be inserted vaginally. The purpose of this research project is to evaluate the dose response of the Endometrin when determined based on the blood level of progesterone on the day of the FET. According to the literature, a predefined level of progesterone in the blood should be reached in order to have favorable conditions for pregnancy. The hypothesis being that a woman with low progesterone levels would benefit from a dose of Endometrin of 600 mg (200 mg 3x/day) to decrease the risk of miscarriage and improve the chances of pregnancy. Women with adequate progesterone levels according to the literature, would continue with the standard dose of progesterone prescribed at clinique ovo which is 300 mg (100 mg 3x/day). PIBF (Progesterone Induced Blocking Factor) levels, a protein found in the blood that could also predict pregnancy outcomes in women using IVF will also be looked at.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 150
Est. completion date June 30, 2026
Est. primary completion date September 30, 2025
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 42 Years
Eligibility Inclusion Criteria: - Women 18-42 years of age - Normal uterine cavity (according to treating physician) - FET substituted cycle prescribed - First or second cycle of FET - Adequate endometrial pattern (triple layer) and thickness (>7 mm) after adequate standard endometrial preparation in artificial cycle Exclusion Criteria: - Any uterine abnormalities confirmed by treating physician making participant unable to proceed with FET - Patients with personalized FET according to the endometrial receptivity assay tests - Previous allergic reactions to progesterone or any of the ingredients of Endometrin - Severe hepatic dysfunction or disease - Known or suspected breast cancer or genital tract cancer - Known active arterial or venous thromboembolism or severe thrombophlebitis or cerebro-vascular disease, or a history of these events - Diagnosed porphyria - Undiagnosed abnormal vaginal bleeding - Known missed abortion or ectopic pregnancy - Recurrent pregnancy loss excluding biochemical pregnancies - Hypersensitivity to Acetylsalicylic acid (ASA), salicylates, non-steroidal anti-inflammatory drugs (NSAIDs), analgesics, antipyretics or other ingredients in the product or component of the container - Acute gastrointestinal ulcer, history of gastrointestinal ulcers and hemorrhagic diathesis - Active or severe renal disease, or congestive heart failure - History of asthma induced by salicylates or other NSAIDs - Use of methotrexate at doses of 15mg/week or more - Glucose-6-phosphate dehydrogenase (G6PD) deficiency

Study Design


Intervention

Drug:
Progesterone Effervescent Vaginal Tablet
On the day of Frozen Embryo Transfer (FET), women will have a blood test to determine progesterone levels. Depending on the result of progesterone level, the participant will be assigned to either the Endometrin 100 mg TID dose or the Endometrin 200 mg TID dose

Locations

Country Name City State
Canada Clinique Ovo Montreal Quebec

Sponsors (2)

Lead Sponsor Collaborator
Clinique Ovo Ferring Pharmaceuticals

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Other Blood test to evaluate the prevalence of PIBF Progesterone Inducing Blocking Factor (PIBF) has been found to to have an important part in creating a welcoming environment for the embryo Before embryo transfer and 10 days after embryo transfer
Primary Evaluate the ongoing pregnancy rate Viability ultrasound 6 to 8 weeks after Frozen Embryo Transfer
Secondary Evaluate the miscarriage rate Viability ultrasound 6 to 8 weeks after Frozen Embryo Transfer
Secondary Evaluate progesterone levels Progesterone levels will be tested at two different times Before embryo transfer and 10 days after embryo transfer
Secondary Evaluate the rate of biochemical pregnancy Serum pregnancy test to measure Beta Human Chorionic Gonadotropin (BhCG) levels 10 days after frozen embryo transfer
See also
  Status Clinical Trial Phase
Recruiting NCT06387498 - Testicular Tissue Cryopreservation (TTC) N/A
Recruiting NCT04519593 - ABSOLUTELY: A Temporary Uterine Blood Supply Occlusion for Laparoscopic Myomectomy in Patients With UTErine LeiomYoma N/A
Recruiting NCT05980091 - Optimal Timing of Euploid Day 6 Blastocyst Transfer in Frozen HRT Cycles, Day 6 or Day 7 of Progesterone Administration. Phase 1
Recruiting NCT06043609 - Outcome Evaluation After Fertility Preservation
Not yet recruiting NCT05048771 - Fertility and Temporality in Pediatric Oncology
Completed NCT05368194 - Food Intake and Epigenetic Alteration in the Spermatozoa of Singletons and Twins N/A
Recruiting NCT05176535 - Determination of Vaginal Colonization and the Effect of an Oral Probiotic (PROSALVAG) N/A
Recruiting NCT06360471 - Fertility Preservation and Pregnancy and Offspring Health Outcomes in Female Cancer
Recruiting NCT05271981 - Fertility After Uterine Artery Embolization
Recruiting NCT05815719 - Continuous Double Ovarian Stimulation. Phase 4
Recruiting NCT06127875 - Effects of Trying to Conceive Using an Home- or Hospital-based Ovulation Monitoring on Stress
Recruiting NCT05658848 - Effect of Collaborative Infertility Counseling on Coping Strategies and Marital Satisfaction N/A
Not yet recruiting NCT05385848 - Autologous Platelet-rich Plasma (PRP) Infusion to Improve Outcomes in Women With Ovarian Insufficiency: a Pilot Study N/A
Completed NCT04396210 - Patients Perspectives on Discontinuation of Their Fertility Treatment Due to the COVID-19 Pandemic
Completed NCT05134090 - Percutaneous Laparoscopy for Ovarian Tissue Cryopreservation.
Completed NCT05905289 - Survival and Reproductive Outcomes of Malignant Ovarian Germ Cell Tumors
Recruiting NCT05316467 - Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma Phase 2/Phase 3
Completed NCT04600869 - Effects of Naturalistic Decision-Making Model-based Oncofertility Care Education N/A
Withdrawn NCT04683237 - Liraglutide Plus Megestrol Acetate in Endometrial Atypical Hyperplasia Phase 2/Phase 3
Not yet recruiting NCT06179420 - The Effectiveness of Advanced Decision Support Tool (OPT-IVF) for IVF Treatment